Header Logo

Connection

Nancy Reau to Humans

Back to Details
This is a "connection" page, showing publications Nancy Reau has written about Humans.
Nancy Reau
Connection Strength
1.664
Humans
  1. Patients With Autoimmune Hepatitis and Nonalcoholic Fatty Liver Disease: Characteristics, Treatment, and Outcomes. J Clin Gastroenterol. 2024 Jan 01; 58(1):91-97.
    View in: PubMed
    Score: 0.051
  2. What Is the Real Epidemiology of Hepatitis D Virus and Why so Many Mixed Messages? Clin Liver Dis. 2023 11; 27(4):973-984.
    View in: PubMed
    Score: 0.050
  3. Use of tecovirimat for mpox infection followed by JYNNEOS vaccination postinfection in a liver transplant recipient. Transpl Infect Dis. 2023 Jun; 25(3):e14030.
    View in: PubMed
    Score: 0.048
  4. Evaluation of Liver Disease in Pregnancy. Clin Liver Dis. 2023 02; 27(1):133-155.
    View in: PubMed
    Score: 0.047
  5. The Spectrum of Hepatic Critical Care During Pregnancy: A Clinical Review. Clin Obstet Gynecol. 2023 03 01; 66(1):176-185.
    View in: PubMed
    Score: 0.047
  6. Liver Disease During Pregnancy. Am J Gastroenterol. 2022 10 01; 117(10S):44-52.
    View in: PubMed
    Score: 0.047
  7. Sustained Impact of the Coronavirus Disease 2019 Pandemic on Hepatitis C Virus Treatment Initiations in the United States. Clin Infect Dis. 2022 Aug 24; 75(1):e955-e961.
    View in: PubMed
    Score: 0.047
  8. The American Association for the Study of Liver Diseases: A history of the first 10 years and its presidents. Hepatology. 2022 09; 76(3):854-859.
    View in: PubMed
    Score: 0.046
  9. An international survey on patterns of practice in NAFLD and expectations for therapies-The POP-NEXT project. Hepatology. 2022 12; 76(6):1766-1777.
    View in: PubMed
    Score: 0.046
  10. Epidemiology and Clinical Characteristics of Individuals with Hepatitis C Virus Infection in the United States, 2017-2019. Adv Ther. 2021 12; 38(12):5777-5790.
    View in: PubMed
    Score: 0.044
  11. Potential Bias and Misconceptions in Liver Transplantation for Alcohol- and Obesity-Related Liver Disease. Am J Gastroenterol. 2021 10 01; 116(10):2089-2097.
    View in: PubMed
    Score: 0.044
  12. Had Anyone Considered the Donors? Fertility and Pregnancy Outcomes Among Female Living Donors. Liver Transpl. 2021 09; 27(9):1235-1236.
    View in: PubMed
    Score: 0.043
  13. Changing epidemiology, implications, and recommendations for hepatitis C in women of childbearing age and during pregnancy. J Hepatol. 2021 03; 74(3):734-741.
    View in: PubMed
    Score: 0.041
  14. Estimating the Year Each State in the United States Will Achieve the World Health Organization's Elimination Targets for Hepatitis?C. Adv Ther. 2021 01; 38(1):423-440.
    View in: PubMed
    Score: 0.041
  15. Review article: a treatment algorithm for patients with chronic liver disease and severe thrombocytopenia undergoing elective medical procedures in the United States. Aliment Pharmacol Ther. 2020 10; 52(8):1311-1322.
    View in: PubMed
    Score: 0.041
  16. HCV in Women and Pregnancy. Hepatology. 2019 11; 70(5):1836-1840.
    View in: PubMed
    Score: 0.038
  17. Medication Non-adherence in a Prospective, Multi-center Cohort Treated with Hepatitis C Direct-Acting Antivirals. J Gen Intern Med. 2020 04; 35(4):1011-1020.
    View in: PubMed
    Score: 0.038
  18. Liver Diseases During Pregnancy. Clin Liver Dis. 2019 05; 23(2):345-361.
    View in: PubMed
    Score: 0.037
  19. Glecaprevir/Pibrentasvir Treatment in Liver or Kidney Transplant Patients With Hepatitis C Virus Infection. Hepatology. 2018 10; 68(4):1298-1307.
    View in: PubMed
    Score: 0.035
  20. Pregnancy after liver transplantation: Can renal function quell the fear? Liver Transpl. 2018 05; 24(5):583-584.
    View in: PubMed
    Score: 0.035
  21. Report from the International Conference on Viral Hepatitis - 2017. AIDS Rev. 2018 Jan-Mar; 20(1):58-70.
    View in: PubMed
    Score: 0.034
  22. HBV reactivation after HCV eradication: Deja Vu. Liver Int. 2017 07; 37(7):1088.
    View in: PubMed
    Score: 0.033
  23. Updates on hepatitis C virus therapy in the direct-acting antiviral era. Curr Opin Gastroenterol. 2017 May; 33(3):115-119.
    View in: PubMed
    Score: 0.032
  24. Generic medications for hepatitis C. Liver Int. 2016 07; 36(7):925-8.
    View in: PubMed
    Score: 0.030
  25. Safety and Efficacy of Ombitasvir/Paritaprevir/Ritonavir Plus Dasabuvir With or Without Ribavirin in HCV-Infected Patients Taking Concomitant Acid-Reducing Agents. Am J Gastroenterol. 2016 06; 111(6):845-51.
    View in: PubMed
    Score: 0.030
  26. The Burden of Rehospitalization for Patients With Liver Cirrhosis. Hosp Pract (1995). 2016; 44(1):60-9.
    View in: PubMed
    Score: 0.030
  27. ACG Clinical Guideline: Liver Disease and Pregnancy. Am J Gastroenterol. 2016 Feb; 111(2):176-94; quiz 196.
    View in: PubMed
    Score: 0.030
  28. HCV Council--critical appraisal of data: recommendations for clinical practice in a rapidly evolving therapeutic landscape. Liver Int. 2016 Apr; 36(4):488-502.
    View in: PubMed
    Score: 0.029
  29. Evaluation of Hepatitis C Patients in the Direct-Acting Antiviral Era. Clin Liver Dis. 2015 Nov; 19(4):591-604, v.
    View in: PubMed
    Score: 0.029
  30. Sticker shock and the price of new therapies for hepatitis C: is it worth it? Hepatology. 2014 Apr; 59(4):1246-9.
    View in: PubMed
    Score: 0.026
  31. Finding the needle in the haystack: predicting mortality in pregnancy-related liver disease. Clin Gastroenterol Hepatol. 2014 Jan; 12(1):114-6.
    View in: PubMed
    Score: 0.025
  32. Potential consequences of healthcare recommendations: a focus on the U.S. Preventive Services Task Force. Hepatology. 2013 Jul; 58(1):422-7.
    View in: PubMed
    Score: 0.025
  33. Hepatitis C: management of side effects in the era of direct-acting antivirals. Curr Gastroenterol Rep. 2013 Jan; 15(1):305.
    View in: PubMed
    Score: 0.024
  34. Liver disease in pregnancy. Clin Liver Dis. 2012 May; 16(2):247-69.
    View in: PubMed
    Score: 0.023
  35. Naives, nonresponders, relapsers: who is there left to treat? Clin Liver Dis. 2011 Aug; 15(3):483-95.
    View in: PubMed
    Score: 0.022
  36. Characterization of nonrapid virologic response patients infected with HCV genotype 1 who may relapse after standard therapy with peginterferon plus ribavirin. J Viral Hepat. 2012 Feb; 19(2):94-102.
    View in: PubMed
    Score: 0.021
  37. Evaluation of early null response to pegylated interferon and ribavirin as a predictor of therapeutic nonresponse in patients undergoing treatment for chronic hepatitis C. Am J Gastroenterol. 2011 Mar; 106(3):452-8.
    View in: PubMed
    Score: 0.021
  38. Long-term outcomes after treatment with interferon and ribavirin in HCV patients. J Clin Gastroenterol. 2009 Aug; 43(7):661-71.
    View in: PubMed
    Score: 0.019
  39. Early predictors of anemia in patients with hepatitis C genotype 1 treated with peginterferon alfa-2a (40KD) plus ribavirin. Am J Gastroenterol. 2008 Aug; 103(8):1981-8.
    View in: PubMed
    Score: 0.018
  40. Management of hepatitis B virus. J Antimicrob Chemother. 2008 Aug; 62(2):224-8.
    View in: PubMed
    Score: 0.017
  41. Vanishing bile duct syndrome. Clin Liver Dis. 2008 Feb; 12(1):203-17, x.
    View in: PubMed
    Score: 0.017
  42. Precipitous changes in nomenclature and definitions-NAFLD becomes SLD: Implications for and expectations of AASLD journals. Hepatology. 2023 Dec 01; 78(6):1680-1681.
    View in: PubMed
    Score: 0.013
  43. Precipitous changes in nomenclature and definitions-NAFLD becomes SLD: Implications for and expectations of AASLD journals. Hepatol Commun. 2023 Nov 01; 7(11).
    View in: PubMed
    Score: 0.013
  44. Liver fibrosis and its response to avapritinib in 2 patients with systemic mastocytosis. Blood Adv. 2022 10 25; 6(20):5630-5633.
    View in: PubMed
    Score: 0.012
  45. Differential expression of hepatic cancer stemness and hypoxia markers in residual cancer after locoregional therapies for hepatocellular carcinoma. Hepatol Commun. 2022 11; 6(11):3247-3259.
    View in: PubMed
    Score: 0.012
  46. Cost-effectiveness of Antenatal Rescreening Among Pregnant Women for Hepatitis C in the United States. Clin Infect Dis. 2021 11 02; 73(9):e3355-e3357.
    View in: PubMed
    Score: 0.011
  47. American Association for the Study of Liver Diseases Expert Panel Consensus Statement: Vaccines to Prevent Coronavirus Disease 2019 Infection in Patients With Liver Disease. Hepatology. 2021 08; 74(2):1049-1064.
    View in: PubMed
    Score: 0.011
  48. Willingness to participate in research among black patients with liver disease: A national cross-sectional study. J Viral Hepat. 2021 07; 28(7):982-993.
    View in: PubMed
    Score: 0.011
  49. Patient-reported outcomes 12?months after hepatitis C treatment with direct-acting antivirals: Results from the PROP UP study. Liver Int. 2021 04; 41(4):692-704.
    View in: PubMed
    Score: 0.010
  50. WGO Guidance for the Care of Patients With COVID-19 and Liver Disease. J Clin Gastroenterol. 2021 01; 55(1):1-11.
    View in: PubMed
    Score: 0.010
  51. Efficacy and safety of elbasvir/grazoprevir for 12 weeks in people with hepatitis C virus infection aged 35 years or younger compared with older people: a retrospective integrated analysis. Curr Med Res Opin. 2020 08; 36(8):1325-1332.
    View in: PubMed
    Score: 0.010
  52. Reply to: "Patient-reported symptoms during direct-acting antiviral treatment: A real-life study in HIV-HCV coinfected patients (ANRS?CO13 HEPAVIH)". J Hepatol. 2020 03; 72(3):592-593.
    View in: PubMed
    Score: 0.010
  53. Cost-effectiveness of Universal Hepatitis C Virus Screening of Pregnant Women in the United States. Clin Infect Dis. 2019 11 13; 69(11):1888-1895.
    View in: PubMed
    Score: 0.010
  54. Hepatitis C remains leading indication for listings and receipt of liver transplantation for hepatocellular carcinoma. Dig Liver Dis. 2020 01; 52(1):98-101.
    View in: PubMed
    Score: 0.010
  55. Patient-reported symptoms during and after direct-acting antiviral therapies for chronic hepatitis C: The PROP UP study. J Hepatol. 2019 09; 71(3):486-497.
    View in: PubMed
    Score: 0.009
  56. A comprehensive assessment of patient reported symptom burden, medical comorbidities, and functional well being in patients initiating direct acting antiviral therapy for chronic hepatitis C: Results from a large US multi-center observational study. PLoS One. 2018; 13(8):e0196908.
    View in: PubMed
    Score: 0.009
  57. Psychometric properties of the PROMIS short form measures in a U.S. cohort of 961 patients with chronic hepatitis C prescribed direct acting antiviral therapy. Aliment Pharmacol Ther. 2018 Apr; 47(7):1001-1011.
    View in: PubMed
    Score: 0.008
  58. Resistance analysis in patients with genotype 1-6 HCV infection treated with sofosbuvir/velpatasvir in the phase III studies. J Hepatol. 2018 05; 68(5):895-903.
    View in: PubMed
    Score: 0.008
  59. Hepatitis C Virus Infection Care Pathway-A Report From the American Gastroenterological Association Institute HCV Care Pathway Work Group. Gastroenterology. 2017 05; 152(6):1588-1598.
    View in: PubMed
    Score: 0.008
  60. Patient engagement and study design of PROP UP: A multi-site patient-centered prospective observational study of patients undergoing hepatitis C treatment. Contemp Clin Trials. 2017 06; 57:58-68.
    View in: PubMed
    Score: 0.008
  61. Novel educational interventions in residency increase knowledge of chronic liver disease and career interest in hepatology. Hepatology. 2016 12; 64(6):2210-2218.
    View in: PubMed
    Score: 0.008
  62. Efficacy of Sofosbuvir, Velpatasvir, and GS-9857 in Patients With?Genotype 1 Hepatitis C Virus Infection in an Open-Label, Phase 2 Trial. Gastroenterology. 2016 11; 151(5):893-901.e1.
    View in: PubMed
    Score: 0.008
  63. Ribavirin-Free Regimen With Sofosbuvir and Velpatasvir Is Associated With High Efficacy and Improvement of Patient-Reported Outcomes in Patients With Genotypes 2 and 3 Chronic Hepatitis C: Results From Astral-2 and -3 Clinical Trials. Clin Infect Dis. 2016 10 15; 63(8):1042-1048.
    View in: PubMed
    Score: 0.008
  64. The benefit of paracentesis on hospitalized adults with cirrhosis and ascites. J Gastroenterol Hepatol. 2016 May; 31(5):1025-30.
    View in: PubMed
    Score: 0.008
  65. Sofosbuvir and Velpatasvir for HCV Genotype 2 and 3 Infection. N Engl J Med. 2015 Dec 31; 373(27):2608-17.
    View in: PubMed
    Score: 0.007
  66. Daclatasvir in combination with asunaprevir and beclabuvir for hepatitis C virus genotype 1 infection with compensated cirrhosis. JAMA. 2015 May 05; 313(17):1736-44.
    View in: PubMed
    Score: 0.007
  67. Screening for Zinc Deficiency in Patients with Cirrhosis: When Should We Start? Dig Dis Sci. 2015 Oct; 60(10):3130-5.
    View in: PubMed
    Score: 0.007
  68. Co-management between hospitalist and hepatologist improves the quality of care of inpatients with chronic liver disease. J Clin Gastroenterol. 2014 Apr; 48(4):e30-6.
    View in: PubMed
    Score: 0.007
  69. Preparing for the uncertain yet inevitable: off-label combinations of antiviral agents in hepatitis C virus. Hepatology. 2014 May; 59(5):1688-91.
    View in: PubMed
    Score: 0.006
  70. Use of immune function test in monitoring immunosuppression in liver transplant recipients. Clin Transplant. 2012 Nov-Dec; 26(6):826-32.
    View in: PubMed
    Score: 0.006
  71. Refined prediction of week 12 response and SVR based on week 4 response in HCV genotype 1 patients treated with peginterferon alfa-2a (40KD) and ribavirin. J Hepatol. 2012 Jun; 56(6):1276-82.
    View in: PubMed
    Score: 0.006
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.